Quoin Pharmaceuticals, Ltd. QNRX
3.97 USD -0.05 (-1.37%)
Nov 3, 2026, 3:07 PM EST
3.90 Day range 4.34
3.25 52-week range 23.50
- YTD
- -72.52%
- 1 year
- -61.62%
News
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 16.2% to $4.67 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Cerus…
globenewswire.com Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026 ASHBURN, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
benzinga.com Quoin Pharma Announces Publication Of Peer-Reviewed Paper Introducing QRX003 And Its Mechanism Of Action In Netherton Syndrome – Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published– Case Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient–…
globenewswire.com Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy – Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published – Case Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient –…
benzinga.com Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18 Canaccord Genuity analyst Whitney Ijem initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $18.
benzinga.com Quoin Pharmaceuticals’ Lead Product Candidate QRX003 Granted Orphan Drug Designation By European Medicines Agency For Treatment Of Peeling Skin Syndrome – Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin…
globenewswire.com Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome – Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin…
benzinga.com This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiated coverage on ASBH, QNRX, AXGN and HOOD with bullish ratings and targets; IDXX received a Sector Weight rating.
benzinga.com BTIG Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $14 BTIG analyst Jeet Mukherjee initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $14.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market session. The company's market cap stands at $555.6 million. Profound Medical (NASDAQ:PROF) stock rose 16.98%…
benzinga.com Quoin Pharmaceuticals Announces Publication Acceptance Of QRX003 Netherton Syndrome Manuscript Featuring Pediatric Compassionate-Use Case Report In Dermatology and Therapy Issue Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton SyndromeCase Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s…
globenewswire.com Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome Case Report Details Professor Alan Irvine's Clinical Experience Treating a Pediatric Patient Under Quoin's…
benzinga.com Lake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20 Lake Street analyst Thomas Flaten initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $20.
globenewswire.com Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome – First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy – Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome – Fast Track Designation…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers AEON Biopharma (AMEX:AEON) stock moved upwards by 8.9% to $0.32 during Thursday's after-market session. The company's market cap stands at $11.5 million. Picard Medical (AMEX:PMI) stock moved…
globenewswire.com Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah's Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU Quoin Pharmaceuticals releases a new NETHERTON NOW video featuring Laura Wright-Sexton, MD, who first met her daughter Aminah as a patient in the ICU.
globenewswire.com CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling…
benzinga.com FDA Grants Rare Pediatric Disease Designation For Quoin Pharma’s Lead Asset, QRX003, For Treatment Of Peeling Skin Syndrome Second Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling…
globenewswire.com Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) shares moved…
benzinga.com Dow Gains 100 Points; Chicago PMI Falls In August US stocks up, Dow gains 100 points, S&P 500 and NASDAQ also rise. Communication services up 1.1%, technology down 0.3%. Chicago Business Barometer dips.
benzinga.com Quoin Pharmaceuticals Stock Surges Friday: What's Happening? Shares of Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) are rallying Friday morning following back-to-back pre-market updates detailing positive clinical trial results and a major institutional financing…
benzinga.com Quoin Pharmaceuticals Stock Surges Friday: What's Happening? Shares of Quoin Pharmaceuticals are rallying Friday after pre-market updates on positive trial results and a major institutional financing.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-market session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) stock moved…- benzinga.com Market-Moving News for August 28th AFRM: 13% | Affirm Holdings shares are trading higher after the company reported strong Q4 financial results. GAP: 16% | Gap shares are trading higher after the company reported better-than-expected…
benzinga.com Why Elastic Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket Elastic NV (ESTC) stock rose 21.8% in pre-market trading after reporting strong Q1 results and raising FY27 guidance. Other top gainers include WHLR, QNRX, AEMD, NA, SOLS, HYNE, GAP, AFRM, and ARKR.…
globenewswire.com Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan…
globenewswire.com Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome Interim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha Adjusted Target for Primary Endpoint with Statistical Significance Four of Six (66.7%)…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.- benzinga.com Quoin Pharmaceuticals Q2 EPS $(1.90) Misses $(1.61) Estimate Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.90) per share which missed the analyst consensus estimate of $(1.61) by 18.01 percent. This is a 69.75 percent increase over…
globenewswire.com Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Compassionate Use Program in…
globenewswire.com Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026 ASHBURN, Va., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 41.1% to $0.09 during Friday's after-market session. The market value of their outstanding shares is at $12.7 million. iTonic…
benzinga.com Quoin Pharmaceuticals Receives FDA Clearance Of Its Investigational New Drug Application For QRX003 To Treat Peeling Skin Syndrome Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and EuropeFDA Expressed No Safety Concerns Over Study Design and Duration of…
globenewswire.com Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome Quoin Pharmaceuticals (NASDAQ: QNRX) receives FDA IND clearance for a Phase 2 study of QRX003 in Peeling Skin Syndrome, with initiation expected in 2H 2026- benzinga.com Quoin Pharmaceuticals Issued Notice Of Allowance From U.S. Patent And Trademark Office Titled Combination Treatment For Netherton Syndrome Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the United States
globenewswire.com Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome ASHBURN, Va., June 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Pulsenmore (NASDAQ:PLSM) stock increased by 152.0% to $8.59 during Wednesday's pre-market session. The company's market cap stands at $22.1 million. Catheter Precision (AMEX:VTAK) shares rose…
benzinga.com Why Leifras Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket Leifras Co Ltd (NASDAQ: LFS) rose in pre-market trading after acquiring SWIFT JAPAN for JPY454.6 million. Other gainers include MGN, VTAK, CUPR, QNRX, CCXI, WEN, BNC, CAST, and ALPS. XCH and TOP were…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million. Mobile-health Network…
- benzinga.com Quoin Pharmaceuticals Receives FDA's Conditional Approval For QYLEKI To Treat Netherton Syndrome Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and
globenewswire.com Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA Pivotal Phase 3 Study Expected to…- benzinga.com Quoin Pharmaceuticals Establishes Japanese Subsidiary To Commercialize QRX003 For The Treatment Of Netherton Syndrome Upon Approval By Authorities The formation follows the recent grant of Orphan Drug Designation to QRX003 by Japan's Ministry of Health, Labour and Welfare (MHLW) and supports Quoin's long-term commercial plans in one of its…
globenewswire.com Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003 Supports Quoin's planned direct commercialization of QRX003 in Japan, one of its three core commercial territories Follows recent grant of Orphan Drug Designation to QRX003 by Japan's MHLW ASHBURN,…- benzinga.com Quoin Pharmaceuticals Announces That Four Of Six Children In Its Ongoing Pediatric Netherton Syndrome Compassionate Use Study Were Classified As 'Improved' Or 'Significantly Improved' From Baseline Across Key Clinical Endpoints Six pediatric NS patients are currently enrolled in the program, all under 10 years of age, with the youngest being just 6 months old. Four of the six children in the study were classified as…
globenewswire.com Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved' or ‘Significantly Improved' from Baseline Assessment Across Key Clinical Endpoints All Six Patients…- benzinga.com Quoin Pharmaceuticals QRX003 Receives Japan's Ministry Of Health, Labour And Welfare To Treat Netherton Syndrome Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that Japan's Ministry…
globenewswire.com Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome -Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval- -Follows Orphan Drug Designation, Pediatric Rare Disease…- benzinga.com Quoin Pharmaceuticals Pharmaceuticals Submits Investigational New Drug Application To FDA For Phase II Trial Of Peeling Skin Syndrome Treatment QRX003 The IND submission is supported by clinical observations from Quoin's ongoing investigator-led pediatric PSS study. The initial subject has been treated with QRX003 for over 15 months and significant…
globenewswire.com Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome -First ever IND submission for this disease, which has no current treatment or cure- -Quoin plans Phase 2 study initiation in 2H 2026- -Submission supported by positive initial clinical data from…